CJC-1295 DAC

Compound identifiers & literature

Public database identifiers and a selection of peer-reviewed publications for CJC-1295 with DAC, provided so researchers can verify this compound independently. Each entry links to the primary source.

Selected literature

1. [1]
   Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Endocrinology.

   Three maleimido derivatives of human GRF(1-29) conjugated to serum albumin were tested for growth hormone secretion in cultured rat anterior pituitary cells and administered to rats; the tetrasubstituted analog designated CJC-1295 showed a 4-fold increase in growth hormone area under the curve over a 2-hour period compared with unmodified hGRF(1-29), and remained detectably albumin-bound beyond 24 hours.

   in vitro and rodentPMID 15817669DOI
2. [2]
   Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults The Journal of Clinical Endocrinology and Metabolism.

   Two randomized, double-blind, placebo-controlled ascending-dose trials lasting 28 and 49 days in healthy subjects aged 21-61 measured plasma growth hormone and IGF-I after subcutaneous CJC-1295; the authors reported 2- to 10-fold increases in mean plasma growth hormone for 6 days or more, 1.5- to 3-fold increases in mean plasma IGF-I for 9-11 days, an estimated half-life of 5.8-8.1 days, and no serious adverse reactions in the populations studied.

   human clinical trialPMID 16352683DOI
3. [3]
   Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse American Journal of Physiology. Endocrinology and Metabolism.

   Three groups of 1-week-old GHRH-knockout mice were treated for 5 weeks with 2 micrograms of CJC-1295 at 24-, 48-, or 72-hour intervals, with placebo-treated knockout mice and heterozygous mice as controls; animals dosed every 24 hours showed body weight and length in the normal range, animals dosed every 48 or 72 hours exceeded placebo but were not fully normalized, and total pituitary RNA and GH mRNA were increased.

   rodentPMID 16822960DOI
4. [4]
   Ionescu M, Frohman LA (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog The Journal of Clinical Endocrinology and Metabolism.

   Growth hormone pulsatility was assessed by 20-minute blood sampling over a 12-hour overnight period in healthy men aged 20-40 before and one week after a single injection of 60 or 90 micrograms/kg CJC-1295, in a within-subject before-and-after design without a placebo arm; pulse frequency and magnitude were unaltered, while basal trough growth hormone increased 7.5-fold, mean growth hormone increased 46%, and IGF-I increased 45%, with IGF-I changes not correlating with any measured growth hormone secretion parameter.

   human clinical trialPMID 17018654DOI
5. [5]
   Henninge J, Pepaj M, Hullstein I, Hemmersbach P (2010). Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation Drug Testing and Analysis.

   Liquid chromatography with high-resolution tandem mass spectrometry was applied to an unidentified pharmaceutical preparation submitted in 2009 by Norwegian police and customs authorities; the analysis found a 29-amino-acid peptide with a C-terminal amide function, and the proposed sequence was reported as consistent with a peptide marketed under the name CJC-1295, a substance prohibited under Section S2 of the WADA Prohibited List. Note that the 29-residue species characterised here lacks the Lys30-DAC linker, so this paper documents the non-DAC form rather than the DAC-conjugated molecule described by the identifiers on this page.

   analytical chemistry (mass spectrometry of a seized pharmaceutical preparation; no biological model, in vitro or in vivo)PMID 21204297DOI

These references are provided for scientific context only. They describe published research on this compound and are not evidence of safety or efficacy, not an endorsement of any use, and not medical advice. This product is supplied for laboratory research use only — not for human or animal consumption.